Product Name

  • Name

    Axitinib

  • EINECS 638-771-6
  • CAS No. 319460-85-0
  • Article Data20
  • CAS DataBase
  • Density 1.35 g/cm3
  • Solubility
  • Melting Point 213-215 °C
  • Formula C22H18N4OS
  • Boiling Point 668.9 °C at 760 mmHg
  • Molecular Weight 386.477
  • Flash Point 358.3 °C
  • Transport Information
  • Appearance Off-white solid
  • Safety 60-61
  • Risk Codes 22-50/53
  • Molecular Structure Molecular Structure of 319460-85-0 (Axitinib)
  • Hazard Symbols Xn,N
  • Synonyms AG013736;Benzamide,N-methyl-2-[[3-[(1E)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]-;
  • PSA 95.97000
  • LogP 5.03000

Synthetic route

(E)-N-methyl-2-{[3-(2-(pyridin-2-yl)ethenyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl]thio}benzamide

(E)-N-methyl-2-{[3-(2-(pyridin-2-yl)ethenyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl]thio}benzamide

axitinib
319460-85-0

axitinib

Conditions
ConditionsYield
With toluene-4-sulfonic acid In neat (no solvent) for 0.75h; Milling;99%
With toluene-4-sulfonic acid In methanol; water at 64℃; for 1 - 5h; Product distribution / selectivity;98%
With toluene-4-sulfonic acid In methanol; water at 65℃; for 4h; Reagent/catalyst; Inert atmosphere;95.4%
C22H18N4OS*C4H4O4

C22H18N4OS*C4H4O4

axitinib
319460-85-0

axitinib

Conditions
ConditionsYield
With 1,2-diaminopropan In 1-methyl-pyrrolidin-2-one at 40 - 70℃; for 1h;95%
6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazole ethylacetate solvate

6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazole ethylacetate solvate

axitinib
319460-85-0

axitinib

Conditions
ConditionsYield
In methanol; acetic acid at 60℃;92%
Stage #1: 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazole ethylacetate solvate With toluene-4-sulfonic acid In ethanol at 82℃; for 14h;
Stage #2: With sodium hydrogencarbonate In ethanol; water at 20℃; for 2h;
6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazole p-toluene sulfonic acid salt

6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazole p-toluene sulfonic acid salt

axitinib
319460-85-0

axitinib

Conditions
ConditionsYield
In NaHCO3; ethyl acetate at 65℃;92%
2-vinylpyridine
100-69-6

2-vinylpyridine

2-((3-iodo-1H-indazol-6-yl)thio)-N-methylbenzamide
885126-34-1

2-((3-iodo-1H-indazol-6-yl)thio)-N-methylbenzamide

axitinib
319460-85-0

axitinib

Conditions
ConditionsYield
Stage #1: 2-((3-iodo-1H-indazol-6-yl)thio)-N-methylbenzamide With palladium diacetate; acetic anhydride; N-ethyl-N,N-diisopropylamine; 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene In 1-methyl-pyrrolidin-2-one at 25 - 50℃; Inert atmosphere;
Stage #2: 2-vinylpyridine In 1-methyl-pyrrolidin-2-one at 50 - 95℃; for 12h;
70.68%
With tris-(o-tolyl)phosphine; lithium bromide; palladium diacetate In 2,4-dichlorophenoxyacetic acid dimethylamine at 110℃; for 25h; Product distribution / selectivity; Heck Reaction;
With N,N,N',N'-tetramethyl-1,8-diaminonaphthalene; tris-(o-tolyl)phosphine; lithium bromide; palladium diacetate In DMA at 110℃; for 25h; Product distribution / selectivity; Inert atmosphere;
bromobenzene
108-86-1

bromobenzene

tert-Butyl acrylate
1663-39-4

tert-Butyl acrylate

axitinib
319460-85-0

axitinib

Conditions
ConditionsYield
With triethylamine In neat (no solvent) at 100℃; for 24h; Heck Reaction; Green chemistry;70%
2-mercapto-N-methylbenzamide
20054-45-9

2-mercapto-N-methylbenzamide

(E)-6-bromo-3-(2-(pyridin-2-yl)vinyl)-1H-indazole

(E)-6-bromo-3-(2-(pyridin-2-yl)vinyl)-1H-indazole

axitinib
319460-85-0

axitinib

Conditions
ConditionsYield
With palladium diacetate; N-ethyl-N,N-diisopropylamine; 4,5-bis(diphenylphos4,5-bis(diphenylphosphino)-9,9-dimethylxanthenephino)-9,9-dimethylxanthene In 1,4-dioxane for 48h; Inert atmosphere; Reflux;54%
2-vinylpyridine
100-69-6

2-vinylpyridine

axitinib
319460-85-0

axitinib

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: palladium diacetate; triethylamine; triphenylphosphine; tetrabutylammomium bromide; sodium bromide / neat (no solvent) / 1.5 h / Milling
2: tris-(dibenzylideneacetone)dipalladium(0); caesium carbonate; 4,5-bis(diphenylphos4,5-bis(diphenylphosphino)-9,9-dimethylxanthenephino)-9,9-dimethylxanthene / neat (no solvent) / 0.83 h / Milling
3: toluene-4-sulfonic acid / neat (no solvent) / 0.75 h / Milling
View Scheme
2-vinylpyridine
100-69-6

2-vinylpyridine

N-1 Boc 2-(3-iodo-1H-indazol-6-ylsulfanyl)-N-methyl-benzamide

N-1 Boc 2-(3-iodo-1H-indazol-6-ylsulfanyl)-N-methyl-benzamide

axitinib
319460-85-0

axitinib

Conditions
ConditionsYield
Stage #1: 2-vinylpyridine; N-1 Boc 2-(3-iodo-1H-indazol-6-ylsulfanyl)-N-methyl-benzamide for 2h; Heck Reaction;
Stage #2: With tris-(o-tolyl)phosphine; palladium diacetate In N,N-dimethyl-formamide at 100℃;
Stage #3: With trifluoroacetic acid Product distribution / selectivity;
1,2-bis(diphenylphosphino)ethane; 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridine-2-yl)ethenyl]indazole; mixture of

1,2-bis(diphenylphosphino)ethane; 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridine-2-yl)ethenyl]indazole; mixture of

axitinib
319460-85-0

axitinib

Conditions
ConditionsYield
In tetrahydrofuran at 20 - 65℃; for 18h; Purification / work up;
N-methyl-2-((1-(t-butoxycarbonyl)-3-((1E)-2-(2-pyridinyl)ethenyl)-1H-indazol-6-yl)thio)benzamide

N-methyl-2-((1-(t-butoxycarbonyl)-3-((1E)-2-(2-pyridinyl)ethenyl)-1H-indazol-6-yl)thio)benzamide

axitinib
319460-85-0

axitinib

Conditions
ConditionsYield
With trifluoroacetic acid In N,N-dimethyl-formamide
6-Iodo-1H-indazole
261953-36-0

6-Iodo-1H-indazole

axitinib
319460-85-0

axitinib

Conditions
ConditionsYield
Multi-step reaction with 5 steps
1.1: 4,5-bis(diphenylphos4,5-bis(diphenylphosphino)-9,9-dimethylxanthenephino)-9,9-dimethylxanthene; sodium hydrogencarbonate; tris-(dibenzylideneacetone)dipalladium(0) / 1-methyl-pyrrolidin-2-one / 0.5 h / 25 °C / Inert atmosphere; Large scale
1.2: 3 h / 25 - 50 °C / Inert atmosphere; Large scale
2.1: iodine; potassium hydroxide / 1-methyl-pyrrolidin-2-one; water / 5.5 h / 25 °C / Inert atmosphere; Large scale
3.1: N-ethyl-N,N-diisopropylamine; palladium diacetate; 4,5-bis(diphenylphos4,5-bis(diphenylphosphino)-9,9-dimethylxanthenephino)-9,9-dimethylxanthene / 1-methyl-pyrrolidin-2-one / 50 °C / Inert atmosphere; Large scale
4.1: 1-methyl-pyrrolidin-2-one / 50 - 90 °C / Inert atmosphere; Large scale
5.1: 1,2-diaminopropan / water; tetrahydrofuran / 12.5 h / 50 °C / Inert atmosphere; Large scale
View Scheme
2-((1H-indazol-6-yl)thio)-N-methylbenzamide
944835-85-2

2-((1H-indazol-6-yl)thio)-N-methylbenzamide

axitinib
319460-85-0

axitinib

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1: iodine; potassium hydroxide / 1-methyl-pyrrolidin-2-one; water / 5.5 h / 25 °C / Inert atmosphere; Large scale
2: N-ethyl-N,N-diisopropylamine; palladium diacetate; 4,5-bis(diphenylphos4,5-bis(diphenylphosphino)-9,9-dimethylxanthenephino)-9,9-dimethylxanthene / 1-methyl-pyrrolidin-2-one / 50 °C / Inert atmosphere; Large scale
3: 1-methyl-pyrrolidin-2-one / 50 - 90 °C / Inert atmosphere; Large scale
4: 1,2-diaminopropan / water; tetrahydrofuran / 12.5 h / 50 °C / Inert atmosphere; Large scale
View Scheme
2-((3-iodo-1H-indazol-6-yl)thio)-N-methylbenzamide
885126-34-1

2-((3-iodo-1H-indazol-6-yl)thio)-N-methylbenzamide

axitinib
319460-85-0

axitinib

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: N-ethyl-N,N-diisopropylamine; palladium diacetate; 4,5-bis(diphenylphos4,5-bis(diphenylphosphino)-9,9-dimethylxanthenephino)-9,9-dimethylxanthene / 1-methyl-pyrrolidin-2-one / 50 °C / Inert atmosphere; Large scale
2: 1-methyl-pyrrolidin-2-one / 50 - 90 °C / Inert atmosphere; Large scale
3: 1,2-diaminopropan / water; tetrahydrofuran / 12.5 h / 50 °C / Inert atmosphere; Large scale
View Scheme
N-methyl-2-((1-acetyl-3-((1E)-2-(2-pyridinyl)ethenyl)-1H-indazol-6-yl)thio)benzamide
1639137-80-6

N-methyl-2-((1-acetyl-3-((1E)-2-(2-pyridinyl)ethenyl)-1H-indazol-6-yl)thio)benzamide

axitinib
319460-85-0

axitinib

Conditions
ConditionsYield
With 1,2-diaminopropan In tetrahydrofuran; water at 50℃; for 12.5h; Inert atmosphere; Large scale;28.0 kg
2-mercapto-N-methylbenzamide
20054-45-9

2-mercapto-N-methylbenzamide

axitinib
319460-85-0

axitinib

Conditions
ConditionsYield
Multi-step reaction with 5 steps
1.1: 4,5-bis(diphenylphos4,5-bis(diphenylphosphino)-9,9-dimethylxanthenephino)-9,9-dimethylxanthene; sodium hydrogencarbonate; tris-(dibenzylideneacetone)dipalladium(0) / 1-methyl-pyrrolidin-2-one / 0.5 h / 25 °C / Inert atmosphere; Large scale
1.2: 3 h / 25 - 50 °C / Inert atmosphere; Large scale
2.1: iodine; potassium hydroxide / 1-methyl-pyrrolidin-2-one; water / 5.5 h / 25 °C / Inert atmosphere; Large scale
3.1: N-ethyl-N,N-diisopropylamine; palladium diacetate; 4,5-bis(diphenylphos4,5-bis(diphenylphosphino)-9,9-dimethylxanthenephino)-9,9-dimethylxanthene / 1-methyl-pyrrolidin-2-one / 50 °C / Inert atmosphere; Large scale
4.1: 1-methyl-pyrrolidin-2-one / 50 - 90 °C / Inert atmosphere; Large scale
5.1: 1,2-diaminopropan / water; tetrahydrofuran / 12.5 h / 50 °C / Inert atmosphere; Large scale
View Scheme
(E)-6-nitro-3-[(2-pyridin-2-yl)vinyl]-1H-indazole

(E)-6-nitro-3-[(2-pyridin-2-yl)vinyl]-1H-indazole

axitinib
319460-85-0

axitinib

Conditions
ConditionsYield
Multi-step reaction with 5 steps
1.1: methanesulfonic acid / tetrahydrofuran / 6 h / Reflux
2.1: sodiumsulfide nonahydrate / water; methanol / 60 °C
3.1: acetic acid; sulfuric acid; sodium nitrite / water / 4 h / -5 - 0 °C
3.2: 5.5 h / 0 °C
4.1: potassium carbonate; copper(l) iodide; 2-vinylpyridine / N,N-dimethyl-formamide / 12 h / 100 °C
5.1: water; hydrogenchloride; methanol / 6 h / 60 °C
View Scheme
(Ε)-6-nitro-3-[2-(pyridin-2-yl)ethenyl]-1-(tetrahydro-2H-pyran-2-yl)indazole
886230-75-7

(Ε)-6-nitro-3-[2-(pyridin-2-yl)ethenyl]-1-(tetrahydro-2H-pyran-2-yl)indazole

axitinib
319460-85-0

axitinib

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1.1: sodiumsulfide nonahydrate / water; methanol / 60 °C
2.1: acetic acid; sulfuric acid; sodium nitrite / water / 4 h / -5 - 0 °C
2.2: 5.5 h / 0 °C
3.1: potassium carbonate; copper(l) iodide; 2-vinylpyridine / N,N-dimethyl-formamide / 12 h / 100 °C
4.1: water; hydrogenchloride; methanol / 6 h / 60 °C
View Scheme
Multi-step reaction with 4 steps
1.1: ammonium chloride; iron / water; ethanol / 2 h / 50 °C
2.1: sodium nitrite; acetic acid / water / 2 h / 0 °C
2.2: 1.17 h / 0 °C
2.3: 2.08 h / 0 °C
3.1: bis[1,2-bis(diphenylphosphino)ferrocene]-palladium(0); caesium carbonate / N,N-dimethyl-formamide / 16 h / 80 °C / Inert atmosphere
4.1: toluene-4-sulfonic acid / water; methanol / 4 h / 65 °C / Inert atmosphere
View Scheme
(Ε)-6-amino-3-[2-(pyridin-2-yl)ethenyl]-1-(tetrahydro-2H-pyran-2-yl)indazole
886230-76-8

(Ε)-6-amino-3-[2-(pyridin-2-yl)ethenyl]-1-(tetrahydro-2H-pyran-2-yl)indazole

axitinib
319460-85-0

axitinib

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1.1: acetic acid; sulfuric acid; sodium nitrite / water / 4 h / -5 - 0 °C
1.2: 5.5 h / 0 °C
2.1: potassium carbonate; copper(l) iodide; 2-vinylpyridine / N,N-dimethyl-formamide / 12 h / 100 °C
3.1: water; hydrogenchloride; methanol / 6 h / 60 °C
View Scheme
Multi-step reaction with 3 steps
1.1: sodium nitrite; acetic acid / water / 2 h / 0 °C
1.2: 1.17 h / 0 °C
1.3: 2.08 h / 0 °C
2.1: bis[1,2-bis(diphenylphosphino)ferrocene]-palladium(0); caesium carbonate / N,N-dimethyl-formamide / 16 h / 80 °C / Inert atmosphere
3.1: toluene-4-sulfonic acid / water; methanol / 4 h / 65 °C / Inert atmosphere
View Scheme
6-nitroindazole
7597-18-4

6-nitroindazole

axitinib
319460-85-0

axitinib

Conditions
ConditionsYield
Multi-step reaction with 8 steps
1.1: potassium carbonate; iodine / N,N-dimethyl-formamide / 25 - 60 °C
2.1: potassium carbonate / N,N-dimethyl-formamide / 2.5 h / 60 °C
3.1: potassium carbonate; 1,10-Phenanthroline; copper(l) iodide / N,N-dimethyl-formamide / 8 h / 60 - 100 °C / Inert atmosphere
3.2: 60 °C
4.1: methanesulfonic acid / tetrahydrofuran / 6 h / Reflux
5.1: sodiumsulfide nonahydrate / water; methanol / 60 °C
6.1: acetic acid; sulfuric acid; sodium nitrite / water / 4 h / -5 - 0 °C
6.2: 5.5 h / 0 °C
7.1: potassium carbonate; copper(l) iodide; 2-vinylpyridine / N,N-dimethyl-formamide / 12 h / 100 °C
8.1: water; hydrogenchloride; methanol / 6 h / 60 °C
View Scheme
Multi-step reaction with 7 steps
1.1: 2,3-dicyano-5,6-dichloro-p-benzoquinone / acetonitrile / 2 h / 82 °C
2.1: sodium hydroxide; iodine / N,N-dimethyl-formamide / 14 h / 10 - 25 °C
2.2: 0.5 h / 20 °C
3.1: N-ethyl-N,N-diisopropylamine; tris-(o-tolyl)phosphine; palladium dichloride / N,N-dimethyl-formamide / 12 h / 100 °C / Inert atmosphere
4.1: ammonium chloride; iron / water; ethanol / 2 h / 50 °C
5.1: sodium nitrite; acetic acid / water / 2 h / 0 °C
5.2: 1.17 h / 0 °C
5.3: 2.08 h / 0 °C
6.1: bis[1,2-bis(diphenylphosphino)ferrocene]-palladium(0); caesium carbonate / N,N-dimethyl-formamide / 16 h / 80 °C / Inert atmosphere
7.1: toluene-4-sulfonic acid / water; methanol / 4 h / 65 °C / Inert atmosphere
View Scheme
(Ε)-6-iodo-3-[2-(pyridin-2-yl)ethenyl]-1-(tetrahydro-2H-pyran-2-yl)indazole

(Ε)-6-iodo-3-[2-(pyridin-2-yl)ethenyl]-1-(tetrahydro-2H-pyran-2-yl)indazole

2-mercapto-N-methylbenzamide
20054-45-9

2-mercapto-N-methylbenzamide

axitinib
319460-85-0

axitinib

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: potassium carbonate; copper(l) iodide; 2-vinylpyridine / N,N-dimethyl-formamide / 12 h / 100 °C
2: water; hydrogenchloride; methanol / 6 h / 60 °C
View Scheme
2,2'-dithiobenzoic acid
119-80-2

2,2'-dithiobenzoic acid

axitinib
319460-85-0

axitinib

Conditions
ConditionsYield
Multi-step reaction with 5 steps
1: thionyl chloride / N,N-dimethyl-formamide / 4 h / Reflux
2: tetrahydrofuran / 11 h / 0 - 20 °C / pH 9 - 10
3: sodium tetrahydroborate / tetrahydrofuran / 0 - 30 °C
4: potassium carbonate; copper(l) iodide; 2-vinylpyridine / N,N-dimethyl-formamide / 12 h / 100 °C
5: water; hydrogenchloride; methanol / 6 h / 60 °C
View Scheme
2,2'-dithiodibenzoic acid dichloride
19602-82-5

2,2'-dithiodibenzoic acid dichloride

axitinib
319460-85-0

axitinib

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1: tetrahydrofuran / 11 h / 0 - 20 °C / pH 9 - 10
2: sodium tetrahydroborate / tetrahydrofuran / 0 - 30 °C
3: potassium carbonate; copper(l) iodide; 2-vinylpyridine / N,N-dimethyl-formamide / 12 h / 100 °C
4: water; hydrogenchloride; methanol / 6 h / 60 °C
View Scheme
2,2'-dithiobis(N-methylbenzamide)
2527-58-4

2,2'-dithiobis(N-methylbenzamide)

axitinib
319460-85-0

axitinib

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: sodium tetrahydroborate / tetrahydrofuran / 0 - 30 °C
2: potassium carbonate; copper(l) iodide; 2-vinylpyridine / N,N-dimethyl-formamide / 12 h / 100 °C
3: water; hydrogenchloride; methanol / 6 h / 60 °C
View Scheme
3-iodo-6-nitro-1H-indazole
70315-70-7

3-iodo-6-nitro-1H-indazole

axitinib
319460-85-0

axitinib

Conditions
ConditionsYield
Multi-step reaction with 7 steps
1.1: potassium carbonate / N,N-dimethyl-formamide / 2.5 h / 60 °C
2.1: potassium carbonate; 1,10-Phenanthroline; copper(l) iodide / N,N-dimethyl-formamide / 8 h / 60 - 100 °C / Inert atmosphere
2.2: 60 °C
3.1: methanesulfonic acid / tetrahydrofuran / 6 h / Reflux
4.1: sodiumsulfide nonahydrate / water; methanol / 60 °C
5.1: acetic acid; sulfuric acid; sodium nitrite / water / 4 h / -5 - 0 °C
5.2: 5.5 h / 0 °C
6.1: potassium carbonate; copper(l) iodide; 2-vinylpyridine / N,N-dimethyl-formamide / 12 h / 100 °C
7.1: water; hydrogenchloride; methanol / 6 h / 60 °C
View Scheme
1-acetyl-3-iodine-6-nitroindazole

1-acetyl-3-iodine-6-nitroindazole

axitinib
319460-85-0

axitinib

Conditions
ConditionsYield
Multi-step reaction with 6 steps
1.1: potassium carbonate; 1,10-Phenanthroline; copper(l) iodide / N,N-dimethyl-formamide / 8 h / 60 - 100 °C / Inert atmosphere
1.2: 60 °C
2.1: methanesulfonic acid / tetrahydrofuran / 6 h / Reflux
3.1: sodiumsulfide nonahydrate / water; methanol / 60 °C
4.1: acetic acid; sulfuric acid; sodium nitrite / water / 4 h / -5 - 0 °C
4.2: 5.5 h / 0 °C
5.1: potassium carbonate; copper(l) iodide; 2-vinylpyridine / N,N-dimethyl-formamide / 12 h / 100 °C
6.1: water; hydrogenchloride; methanol / 6 h / 60 °C
View Scheme
1,3-dibromobenzene
108-36-1

1,3-dibromobenzene

axitinib
319460-85-0

axitinib

Conditions
ConditionsYield
Multi-step reaction with 6 steps
1: aluminum (III) chloride / 1 h / 100 °C / Inert atmosphere
2: potassium hydroxide / methanol; water / 1.5 h / 20 °C
3: hydrogenchloride / methanol; water / 12 h / 50 °C
4: copper(I) oxide / i-Amyl alcohol / 5 h / Inert atmosphere; Reflux
5: tetrabutyl ammonium fluoride / tetrahydrofuran / 12 h / 50 °C
6: N-ethyl-N,N-diisopropylamine; 4,5-bis(diphenylphos4,5-bis(diphenylphosphino)-9,9-dimethylxanthenephino)-9,9-dimethylxanthene; palladium diacetate / 1,4-dioxane / 48 h / Inert atmosphere; Reflux
View Scheme
2,4-dibromoacetophenone
33243-33-3

2,4-dibromoacetophenone

axitinib
319460-85-0

axitinib

Conditions
ConditionsYield
Multi-step reaction with 5 steps
1: potassium hydroxide / methanol; water / 1.5 h / 20 °C
2: hydrogenchloride / methanol; water / 12 h / 50 °C
3: copper(I) oxide / i-Amyl alcohol / 5 h / Inert atmosphere; Reflux
4: tetrabutyl ammonium fluoride / tetrahydrofuran / 12 h / 50 °C
5: N-ethyl-N,N-diisopropylamine; 4,5-bis(diphenylphos4,5-bis(diphenylphosphino)-9,9-dimethylxanthenephino)-9,9-dimethylxanthene; palladium diacetate / 1,4-dioxane / 48 h / Inert atmosphere; Reflux
View Scheme
(E)-1-(2,4-dibromophenyl)-3-(pyridin-2-yl)prop-2-en-1-one

(E)-1-(2,4-dibromophenyl)-3-(pyridin-2-yl)prop-2-en-1-one

axitinib
319460-85-0

axitinib

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1: hydrogenchloride / methanol; water / 12 h / 50 °C
2: copper(I) oxide / i-Amyl alcohol / 5 h / Inert atmosphere; Reflux
3: tetrabutyl ammonium fluoride / tetrahydrofuran / 12 h / 50 °C
4: N-ethyl-N,N-diisopropylamine; 4,5-bis(diphenylphos4,5-bis(diphenylphosphino)-9,9-dimethylxanthenephino)-9,9-dimethylxanthene; palladium diacetate / 1,4-dioxane / 48 h / Inert atmosphere; Reflux
View Scheme
C21H16BrN3O2S

C21H16BrN3O2S

axitinib
319460-85-0

axitinib

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: tetrabutyl ammonium fluoride / tetrahydrofuran / 12 h / 50 °C
2: N-ethyl-N,N-diisopropylamine; 4,5-bis(diphenylphos4,5-bis(diphenylphosphino)-9,9-dimethylxanthenephino)-9,9-dimethylxanthene; palladium diacetate / 1,4-dioxane / 48 h / Inert atmosphere; Reflux
View Scheme
axitinib
319460-85-0

axitinib

(2E)-but-2-enedioic acid
110-17-8

(2E)-but-2-enedioic acid

C22H18N4OS*C4H4O4

C22H18N4OS*C4H4O4

Conditions
ConditionsYield
With palladium In 1-methyl-pyrrolidin-2-one; ethanol at 65 - 75℃; for 1h; Solvent;99.9%
axitinib
319460-85-0

axitinib

acetyl chloride
75-36-5

acetyl chloride

N-methyl-2-((1-acetyl-3-((1E)-2-(2-pyridinyl)ethenyl)-1H-indazol-6-yl)thio)benzamide
1639137-80-6

N-methyl-2-((1-acetyl-3-((1E)-2-(2-pyridinyl)ethenyl)-1H-indazol-6-yl)thio)benzamide

Conditions
ConditionsYield
In dichloromethane at 20℃; for 16h; Cooling with ice;99%
With triethylamine In dichloromethane at 20℃; for 16h; Cooling with ice; Inert atmosphere;99%
axitinib
319460-85-0

axitinib

2-((tert-butyldimethylsilyl)oxy)ethyl (4-nitrophenyl) carbonate

2-((tert-butyldimethylsilyl)oxy)ethyl (4-nitrophenyl) carbonate

C31H36N4O4SSi

C31H36N4O4SSi

Conditions
ConditionsYield
With triethylamine In N,N-dimethyl-formamide at 20℃; for 16h;98%
2,3-dihydro-2H-furan
1191-99-7

2,3-dihydro-2H-furan

axitinib
319460-85-0

axitinib

N-methyl-2-((3-((E)-2-(2-pyridyl)vinyl)-1-(tetrahydrofuran-2-yl)-1H-indazol-6-yl)thio)benzamide

N-methyl-2-((3-((E)-2-(2-pyridyl)vinyl)-1-(tetrahydrofuran-2-yl)-1H-indazol-6-yl)thio)benzamide

Conditions
ConditionsYield
With toluene-4-sulfonic acid In N,N-dimethyl-formamide at 80℃; for 2h;96%
axitinib
319460-85-0

axitinib

p-nitrophenyl 13,13,14,14-tetramethyl-3,6,9,12-tetraoxa-13-silapentadec-1-yl carbonate

p-nitrophenyl 13,13,14,14-tetramethyl-3,6,9,12-tetraoxa-13-silapentadec-1-yl carbonate

N-methyl-2-((1-(13-hydroxy-1-oxo-2,5,8,11-tetraoxatridec-1-yl)-3-((1E)-2-(2-pyridinyl)ethenyl)-1H-indazol-6-yl)thio)benzamide hydrochloride

N-methyl-2-((1-(13-hydroxy-1-oxo-2,5,8,11-tetraoxatridec-1-yl)-3-((1E)-2-(2-pyridinyl)ethenyl)-1H-indazol-6-yl)thio)benzamide hydrochloride

Conditions
ConditionsYield
Stage #1: axitinib; p-nitrophenyl 13,13,14,14-tetramethyl-3,6,9,12-tetraoxa-13-silapentadec-1-yl carbonate With triethylamine In N,N-dimethyl-formamide at 20℃;
Stage #2: With hydrogenchloride; ethanol at 20℃; for 2h;
95.3%
axitinib
319460-85-0

axitinib

N-tert-butoxycarbonyl aspartic acid tert-butyl ester
34582-32-6

N-tert-butoxycarbonyl aspartic acid tert-butyl ester

N-methyl-2-((3-((E)-2-(2-pyridyl)vinyl)-1-(β-L-aspartyl)-1H-indazole-6-yl)thio)benzamide

N-methyl-2-((3-((E)-2-(2-pyridyl)vinyl)-1-(β-L-aspartyl)-1H-indazole-6-yl)thio)benzamide

Conditions
ConditionsYield
With diphenylphosphoranyl azide; triethylamine In N,N-dimethyl-formamide at 20℃; for 4h;93.6%
axitinib
319460-85-0

axitinib

N-tert-butoxycarbonyl aspartic acid tert-butyl ester
34582-32-6

N-tert-butoxycarbonyl aspartic acid tert-butyl ester

C31H31N5O6S

C31H31N5O6S

Conditions
ConditionsYield
With diphenyl phosphoryl azide; triethylamine In N,N-dimethyl-formamide at 20℃; for 4h;93.6%
axitinib
319460-85-0

axitinib

formaldehyd
50-00-0

formaldehyd

N-methyl-2-((3-((E)-2-(2-pyridyl)vinyl)-1-hydroxymethyl-1H-indazol-6-yl)thio)benzamide

N-methyl-2-((3-((E)-2-(2-pyridyl)vinyl)-1-hydroxymethyl-1H-indazol-6-yl)thio)benzamide

Conditions
ConditionsYield
With triethylamine In water; N,N-dimethyl-formamide at 0℃; for 3h;93%
axitinib
319460-85-0

axitinib

4-Nitrophenyl chloroformate
7693-46-1

4-Nitrophenyl chloroformate

C29H21N5O5S*(x)ClH

C29H21N5O5S*(x)ClH

Conditions
ConditionsYield
In tetrahydrofuran at 80℃; for 7h;92%
2-(2-(2-methoxyethoxy)ethoxy)ethyl (4-nitrophenyl) carbonate

2-(2-(2-methoxyethoxy)ethoxy)ethyl (4-nitrophenyl) carbonate

axitinib
319460-85-0

axitinib

N-methyl-2-((3-((E)-2-(2-pyridyl)vinyl)-1-((3,6,9-trioxadecane-1-yl)oxycarbonyl)-1H-indazol-6-yl)thio)benzamide

N-methyl-2-((3-((E)-2-(2-pyridyl)vinyl)-1-((3,6,9-trioxadecane-1-yl)oxycarbonyl)-1H-indazol-6-yl)thio)benzamide

Conditions
ConditionsYield
With triethylamine In N,N-dimethyl-formamide at 20℃;89%
With triethylamine In N,N-dimethyl-formamide at 20℃;89%
axitinib
319460-85-0

axitinib

(2-(2-((tert-butyldimethylsilyl)oxy)ethoxy)ethyl)(4-nitrophenyl) carbonate

(2-(2-((tert-butyldimethylsilyl)oxy)ethoxy)ethyl)(4-nitrophenyl) carbonate

N-methyl-2-((1-(2-(2-hydroxyethoxy)ethoxycarbonyl)-3-(( 1E)-2-(2-pyridinyl)ethenyl)-1H-indazol-6-yl)thio)benzamide hydrochloride

N-methyl-2-((1-(2-(2-hydroxyethoxy)ethoxycarbonyl)-3-(( 1E)-2-(2-pyridinyl)ethenyl)-1H-indazol-6-yl)thio)benzamide hydrochloride

Conditions
ConditionsYield
Stage #1: axitinib; (2-(2-((tert-butyldimethylsilyl)oxy)ethoxy)ethyl)(4-nitrophenyl) carbonate With triethylamine In N,N-dimethyl-formamide at 20℃;
Stage #2: With hydrogenchloride; ethanol at 20℃; for 2h;
87.8%
axitinib
319460-85-0

axitinib

di-tert-butyl dicarbonate
24424-99-5

di-tert-butyl dicarbonate

N-methyl-2-((1-(t-butoxycarbonyl)-3-((1E)-2-(2-pyridinyl)ethenyl)-1H-indazol-6-yl)thio)benzamide

N-methyl-2-((1-(t-butoxycarbonyl)-3-((1E)-2-(2-pyridinyl)ethenyl)-1H-indazol-6-yl)thio)benzamide

Conditions
ConditionsYield
With triethylamine In N,N-dimethyl-formamide at 20℃;87%
With triethylamine In N,N-dimethyl-formamide at 20℃;77%
With triethylamine In N,N-dimethyl-formamide for 1h;4.1 g
With triethylamine In N,N-dimethyl-formamide for 1h;4.1 g
With triethylamine In N,N-dimethyl-formamide for 1h;4.1 g
axitinib
319460-85-0

axitinib

t-butyl malonate
541-16-2

t-butyl malonate

N-methyl-2-((1-(t-butoxycarbonyl)-3-((1E)-2-(2-pyridinyl)ethenyl)-1H-indazol-6-yl)thio)benzamide

N-methyl-2-((1-(t-butoxycarbonyl)-3-((1E)-2-(2-pyridinyl)ethenyl)-1H-indazol-6-yl)thio)benzamide

Conditions
ConditionsYield
With triethylamine In N,N-dimethyl-formamide at 20℃;87%
axitinib
319460-85-0

axitinib

axitinib hydrobromic acid salt

axitinib hydrobromic acid salt

Conditions
ConditionsYield
With hydrogen bromide In isopropyl alcohol at 20 - 50℃;84%
axitinib
319460-85-0

axitinib

p-nitrophenyl 13,13,14,14-tetramethyl-3,6,9,12-tetraoxa-13-silapentadec-1-yl carbonate

p-nitrophenyl 13,13,14,14-tetramethyl-3,6,9,12-tetraoxa-13-silapentadec-1-yl carbonate

N-methyl-2-((1-(13,13,14,14-tetramethyl-3,6,9,12-tetraoxa-13-silapentadec-1-yl)-3-(( 1E)-2-(2-pyridinyl)ethenyl)-1H-indazol-6-yl)thio)benzamide

N-methyl-2-((1-(13,13,14,14-tetramethyl-3,6,9,12-tetraoxa-13-silapentadec-1-yl)-3-(( 1E)-2-(2-pyridinyl)ethenyl)-1H-indazol-6-yl)thio)benzamide

Conditions
ConditionsYield
With triethylamine In N,N-dimethyl-formamide at 20℃;83.1%
axitinib
319460-85-0

axitinib

axitinib hydrochloric acid salt

axitinib hydrochloric acid salt

Conditions
ConditionsYield
With hydrogenchloride In isopropyl alcohol at 20 - 50℃;83%
axitinib
319460-85-0

axitinib

1-dodecyl p-nitrophenyl carbonate
66398-02-5

1-dodecyl p-nitrophenyl carbonate

N-methyl-2-((1-dodecyloxycarbonyl-3-((1E)-2-(2-pyridinyl)ethenyl)-1H-indazol-6-yl)thio)benzamide

N-methyl-2-((1-dodecyloxycarbonyl-3-((1E)-2-(2-pyridinyl)ethenyl)-1H-indazol-6-yl)thio)benzamide

Conditions
ConditionsYield
With triethylamine In N,N-dimethyl-formamide at 20℃; for 3h;82.3%
With triethylamine In N,N-dimethyl-formamide at 20℃; for 3h;82.3%
axitinib
319460-85-0

axitinib

di-tert-butyl dicarbonate
24424-99-5

di-tert-butyl dicarbonate

6-((2-((t-butoxycarbonyl)(methyl)carbamoyl)phenyl)thio)-3-(2-(pyridin-2-yl)ethylenyl)-1H-indazol-1-carboxylic acid (E)-t-butyl ester

6-((2-((t-butoxycarbonyl)(methyl)carbamoyl)phenyl)thio)-3-(2-(pyridin-2-yl)ethylenyl)-1H-indazol-1-carboxylic acid (E)-t-butyl ester

Conditions
ConditionsYield
With dmap In dichloromethane at 25℃; for 16h;81.9%
axitinib
319460-85-0

axitinib

methanesulfonic acid
75-75-2

methanesulfonic acid

axitinib methanesulfonic acid salt

axitinib methanesulfonic acid salt

Conditions
ConditionsYield
In isopropyl alcohol at 20 - 50℃;81%
axitinib
319460-85-0

axitinib

pivaloyl chloride
3282-30-2

pivaloyl chloride

N-methyl-2-((1-pivaloyl-3-((1E)-2-(2-pyridinyl)ethenyl)-1H-indazol-6-yl)thio)benzamide

N-methyl-2-((1-pivaloyl-3-((1E)-2-(2-pyridinyl)ethenyl)-1H-indazol-6-yl)thio)benzamide

Conditions
ConditionsYield
With triethylamine In dichloromethane at 0 - 20℃; Inert atmosphere;81%
With triethylamine In dichloromethane at 20℃; Inert atmosphere; Cooling with ice;81%
axitinib
319460-85-0

axitinib

4-nitrophenyl (2,2,3,3-tetramethyl-4,7,10-trioxa-3-siladodecan-12-yl) carbonate

4-nitrophenyl (2,2,3,3-tetramethyl-4,7,10-trioxa-3-siladodecan-12-yl) carbonate

C35H44N4O6SSi

C35H44N4O6SSi

Conditions
ConditionsYield
With triethylamine In N,N-dimethyl-formamide81%
axitinib
319460-85-0

axitinib

N-methyl-2-((1-(2-(2-(tert-butyldimethylsilyloxy)ethoxy)ethoxycarbonyl)-3-((1E)-2-(2-pyridinyl)ethenyl)-1H-indazol-6-yl)thio)benzamide

N-methyl-2-((1-(2-(2-(tert-butyldimethylsilyloxy)ethoxy)ethoxycarbonyl)-3-((1E)-2-(2-pyridinyl)ethenyl)-1H-indazol-6-yl)thio)benzamide

Conditions
ConditionsYield
With triethylamine In N,N-dimethyl-formamide at 20℃;81%
axitinib
319460-85-0

axitinib

(2-(2-methoxyethoxy)ethyl) (4-nitrophenyl) carbonate
105108-59-6

(2-(2-methoxyethoxy)ethyl) (4-nitrophenyl) carbonate

N-methyl-2-((1-(1-oxo-2,5,8-trioxanayl)-3-((1E)-2-(2-pyridinyl)ethenyl)-1H-indazol-6-yl)thio)benzamide

N-methyl-2-((1-(1-oxo-2,5,8-trioxanayl)-3-((1E)-2-(2-pyridinyl)ethenyl)-1H-indazol-6-yl)thio)benzamide

Conditions
ConditionsYield
With triethylamine In N,N-dimethyl-formamide at 20℃; for 3h;80.6%
axitinib
319460-85-0

axitinib

4-nitrophenyl (2,2,3,3-tetramethyl-4,7,10-trioxa-3-siladodecan-12-yl) carbonate

4-nitrophenyl (2,2,3,3-tetramethyl-4,7,10-trioxa-3-siladodecan-12-yl) carbonate

N-methyl-2-((1-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxycarbonyl)-3-((1E)-2-(2-pyridinyl)ethenyl)-1H-indazol-6-yl)thio)benzamide hydrochloride

N-methyl-2-((1-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxycarbonyl)-3-((1E)-2-(2-pyridinyl)ethenyl)-1H-indazol-6-yl)thio)benzamide hydrochloride

Conditions
ConditionsYield
Stage #1: axitinib; 4-nitrophenyl (2,2,3,3-tetramethyl-4,7,10-trioxa-3-siladodecan-12-yl) carbonate With triethylamine In N,N-dimethyl-formamide at 20℃;
Stage #2: With hydrogenchloride; ethanol at 20℃; for 2h;
79.8%
axitinib
319460-85-0

axitinib

methyl (2-ethoxy)(4-nitrophenyl)carbonate
426264-10-0

methyl (2-ethoxy)(4-nitrophenyl)carbonate

N-methyl-2-((3-((E)-2-(2-pyridyl)vinyl)-1-((2-methoxy-1-ethyl)oxycarbonyl)-1H-indazol-6-yl)thio)benzamide

N-methyl-2-((3-((E)-2-(2-pyridyl)vinyl)-1-((2-methoxy-1-ethyl)oxycarbonyl)-1H-indazol-6-yl)thio)benzamide

Conditions
ConditionsYield
With triethylamine In N,N-dimethyl-formamide at 20℃; for 3h;79.8%
With triethylamine In N,N-dimethyl-formamide at 20℃; for 3h;79.8%
axitinib
319460-85-0

axitinib

4-nitrophenyl n-pentyl carbonate
67036-14-0

4-nitrophenyl n-pentyl carbonate

N-methyl-2-((3-((E)-2-(2-pyridyl)vinyl)-1-pentyloxycarbonyl-1H-indazol-6-yl)sulfanyl)benzamide

N-methyl-2-((3-((E)-2-(2-pyridyl)vinyl)-1-pentyloxycarbonyl-1H-indazol-6-yl)sulfanyl)benzamide

Conditions
ConditionsYield
With triethylamine at 20℃; for 3h;77%
With triethylamine In N,N-dimethyl-formamide at 20℃; for 3h;77%

Axitinib Specification

1. Introduction of Axitinib
Axitinib is one kind of white crystalline powder or off-white solid. The IUPAC name of Axitinib is N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide. The product's categories are All Inhibitors; Inhibitors; Intermediates & Fine Chemicals; Pharmaceuticals; Protein Kinase Inhibitors and Activators. It is a small molecule tyrosine kinase inhibitor under development by Pfizer. Axitinib can soluble in DMSO at 33 mg/mL; soluble in ethanol at 1.7 mg/mL with warming; very poorly soluble in water; maximum solubility in plain water is estimated to be about 10-50 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility.

2. Properties of Axitinib
Physical properties about Axitinib are:
(1)ACD/LogP: 4.15; (2)# of Rule of 5 Violations: 0; (3)ACD/LogD (pH 5.5): 4.14; (4)ACD/LogD (pH 7.4): 4.15; (5)ACD/BCF (pH 5.5): 830.65; (6)ACD/BCF (pH 7.4): 834.47; (7)ACD/KOC (pH 5.5): 4273.12; (8)ACD/KOC (pH 7.4): 4292.77; (9)#H bond acceptors: 5; (10)#H bond donors: 2; (11)#Freely Rotating Bonds: 5; (12)Polar Surface Area: 76.32 Å2; (13)Index of Refraction: 1.728; (14)Molar Refractivity: 113.45 cm3; (15)Molar Volume: 284.8 cm3; (16)Polarizability: 44.97×10-24 cm3; (17)Surface Tension: 75.2 dyne/cm; (18)Density: 1.35 g/cm3; (19)Flash Point: 358.3 °C; (20)Enthalpy of Vaporization: 98.31 kJ/mol; (21)Boiling Point: 668.9 °C at 760 mmHg; (22)Vapour Pressure: 9.35E-18 mmHg at 25°C.

3. Structure Descriptors of Axitinib
(1)SMILES:O=C(NC)c4ccccc4Sc1ccc2c(c1)nnc2\C=C\c3ncccc3
(2)InChI:InChI=1/C22H18N4OS/c1-23-22(27)18-7-2-3-8-21(18)28-16-10-11-17-19(25-26-20(17)14-16)12-9-15-6-4-5-13-24-15/h2-14H,1H3,(H,23,27)(H,25,26)/b12-9+ 
(3)InChIKey:RITAVMQDGBJQJZ-FMIVXFBMBT
(4)Std. InChI:InChI=1S/C22H18N4OS/c1-23-22(27)18-7-2-3-8-21(18)28-16-10-11-17-19(25-26-20(17)14-16)12-9-15-6-4-5-13-24-15/h2-14H,1H3,(H,23,27)(H,25,26)/b12-9+
(5)Std. InChIKey:RITAVMQDGBJQJZ-FMIVXFBMSA-N

4. Uses of Axitinib
Axitinib (AG-013736) is an oral, potent, and selective inhibitor of vascular endothelial growth factor receptors 1 (VEGFR-1), 2 (VEGFR-2), and 3 (VEGFR-3), platelet derived growth factor receptor (PDGFR), and cKIT (CD117). Axitinib inhibits many targets which is including VEGFR-1, VEGFR-2, VEGFR-3, platelet derived growth factor receptor (PDGFR), and cKIT (CD117). It also can inhibit growth of breast cancer in xenograft models and has been successful in trials with renal cell carcinoma (RCC) and several other tumor types. A Phase II clinical trial showed good response in combination chemotherapy with gemcitabine for advanced pancreatic cancer.

Post buying leads

About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia

Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog

©2008 LookChem.com,License: ICP

NO.:Zhejiang16009103

complaints:service@lookchem.com Desktop View